Do You Lose Muscle on Mounjaro — and How Much Does It Matter?

Does Mounjaro specifically cause muscle loss, or is this just what weight loss does?

A common worry (and an understandable one) is that tirzepatide somehow targets muscle. It doesn't. Tirzepatide acts on GIP and GLP-1 receptors to reduce appetite and slow gastric emptying; it has no direct mechanism that breaks down muscle tissue. The lean-mass reduction seen in trials is the same phenomenon that happens whenever the body runs a sustained calorie deficit: it draws on both fat and lean stores for energy. The question is proportion, not a drug-specific effect.

In the SURMOUNT-1 trial (a 72-week study involving 2,539 adults with obesity) participants at the 15 mg dose lost roughly 20–22% of body weight on average. Body-composition sub-studies suggested approximately 70–75% of that was fat mass, with lean mass accounting for the rest. For context, similar body-composition analyses of other calorie-deficit interventions, including bariatric surgery, show comparable splits. Tirzepatide does not appear to perform worse than other approaches on this measure, and some analyses suggest the fat-to-lean ratio is at least as favourable as diet alone. The full Mounjaro overview covers how tirzepatide works in more detail.

If you've read that GLP-1 treatments cause unusual muscle wasting, that claim goes beyond what the current evidence supports. The concern worth taking seriously is whether the proportion is large enough to matter practically, and whether you can shift it.

How much lean mass are we actually talking about, and does it affect strength?

Numbers can feel abstract, so it's worth grounding them. If someone starting at 100 kg loses 20 kg over 72 weeks, around 5 kg of that might be lean mass (including muscle, connective tissue and water bound to glycogen stores). That sounds significant. In practice, the clinical concern is less about the absolute figure and more about whether functional strength declines, whether someone finds stairs harder, whether grip strength falls, whether fatigue increases beyond what a large calorie deficit would ordinarily produce.

Evidence on functional outcomes is still building. Early data from the SURMOUNT programme and real-world follow-up suggest that physical function scores often improve in people who were previously limited by excess weight, even when some lean mass is lost. Carrying less total load matters. That said, older adults and people who already have low muscle mass before starting treatment warrant closer attention, this is one reason the muscle-loss question on tirzepatide is worth exploring with your prescriber before you begin, not after.

One practical note: some of what registers as 'lean mass loss' on DEXA scans is fluid and glycogen, not contractile muscle fibre. Glycogen stores fall as carbohydrate intake drops and as the liver processes fat more actively. This is reversible. The NHS's tirzepatide patient information covers what to expect during treatment.

What actually preserves muscle during Mounjaro treatment?

Three things have the strongest backing in the weight-loss literature: adequate protein intake, resistance-based activity, and not rushing the dose titration beyond your tolerance.

Protein is the most consistently supported lever. Most adults on a calorie deficit benefit from higher protein than general population guidance suggests, somewhere in the range of 1.2–1.6 g per kg of body weight per day is commonly cited in obesity-medicine contexts, though your prescriber or a registered dietitian can give you a personal target. The practical challenge on Mounjaro is that appetite falls sharply, which makes hitting protein targets harder. Prioritising protein at the start of each meal, before appetite fades entirely, is a strategy many people find useful.

Resistance exercise (anything that challenges muscles against load, from gym weights to resistance bands to bodyweight work) is the stimulus that signals the body to maintain muscle even in a deficit. Aerobic activity supports cardiovascular health and mood, but it is resistance work that specifically reduces lean-mass loss during calorie restriction. If cost is part of the picture, the Mounjaro cost page sets out what private treatment includes so you can plan accordingly.

Finally, the dose schedule itself matters indirectly. Tirzepatide starts at 2.5 mg partly to give the body time to adjust; a dose that causes severe nausea can make eating (and adequate protein) genuinely difficult for days at a time. Staying at each dose long enough to tolerate it well before progressing is clinically sound, and it supports better nutrition throughout. The muscle ache and physical symptoms page addresses what's normal when symptoms arise during titration.

Should you be worried enough to reconsider treatment?

For most people assessed as suitable for tirzepatide, the answer is no. The metabolic benefits of significant fat loss (improved blood pressure, insulin sensitivity, lipid profiles and joint load) are well-documented and clinically meaningful. The lean-mass loss seen in trials is real but proportionally modest against those gains, and it is substantially modifiable with the steps above.

The people for whom this question deserves more careful thought are those with pre-existing sarcopenia (low muscle mass relative to body size), older adults, and people with conditions that already limit physical activity. A prescriber who reviews your full history (not just your BMI) can flag these considerations before treatment starts rather than leaving you to manage them mid-course. If Mounjaro didn't work as expected for you in the past, body-composition factors are worth discussing as part of that review too.

NICE's appraisal of tirzepatide, TA1026, sets out the clinical framework within which the medicine is recommended. The clinical decision is always individual. Speak to our prescribers if you'd like to explore whether Mounjaro is right for you, start with a free consultation.